| abstract |
Disclosed are a compound inhibitory of HIF-1 activity, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound has anticancer activity which is attributable to its inhibitory activity against HIF-1, but not to non-selective cellular toxicity. Thus, having inhibitory activity against HIF-1, the compound or a pharmaceutically acceptable salt thereof can be used as an ingredient in an anticancer agent for various cancers including large intestine cancer, hepatic cancer, stomach cancer and breast cancer. Further, the compound or a pharmaceutically acceptable salt thereof is applicable to the treatment of diabetic retinopathy or arthritis which is aggravated upon the activation of VEGFA by HIF-1. |